|
TherateChnologies Inc. (THTX) Avaliação DCF |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Theratechnologies Inc. (THTX) Bundle
Simplifique sua análise e melhore a precisão com a nossa calculadora DCF (thtx)! Utilizando dados reais da TherateChnologies Inc. e suposições personalizáveis, essa ferramenta o capacita a prever, analisar e avaliar (THTX) como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.1 | 69.8 | 80.1 | 81.8 | 85.9 | 91.8 | 98.1 | 104.8 | 112.0 | 119.7 |
| Revenue Growth, % | 0.00 | 5.71 | 14.66 | 2.13 | 5.02 | 6.88 | 6.88 | 6.88 | 6.88 | 6.88 |
| EBITDA | -9.2 | -17.2 | -27.9 | -10.3 | 6.9 | -14.3 | -15.3 | -16.3 | -17.5 | -18.7 |
| EBITDA, % | -13.89 | -24.57 | -34.81 | -12.61 | 8.01 | -15.58 | -15.58 | -15.58 | -15.58 | -15.58 |
| Depreciation | 8.8 | 8.6 | 12.0 | 3.3 | 2.8 | 8.8 | 9.4 | 10.1 | 10.7 | 11.5 |
| Depreciation, % | 13.38 | 12.29 | 15.03 | 4.04 | 3.22 | 9.59 | 9.59 | 9.59 | 9.59 | 9.59 |
| EBIT | -18.0 | -25.7 | -39.9 | -13.6 | 4.1 | -23.1 | -24.7 | -26.4 | -28.2 | -30.1 |
| EBIT, % | -27.28 | -36.86 | -49.84 | -16.65 | 4.80 | -25.17 | -25.17 | -25.17 | -25.17 | -25.17 |
| Total Cash | 20.8 | 40.4 | 33.1 | 40.9 | 9.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 13.2 | 10.9 | 12.3 | 13.6 | 15.6 | 15.8 | 16.8 | 18.0 | 19.2 | 20.5 |
| Account Receivables, % | 19.96 | 15.65 | 15.42 | 16.57 | 18.17 | 17.16 | 17.16 | 17.16 | 17.16 | 17.16 |
| Inventories | 25.1 | 29.1 | 19.7 | 6.1 | 5.3 | 21.7 | 23.1 | 24.7 | 26.4 | 28.2 |
| Inventories, % | 38.07 | 41.74 | 24.59 | 7.42 | 6.15 | 23.59 | 23.59 | 23.59 | 23.59 | 23.59 |
| Accounts Payable | 17.5 | 15.5 | 12.9 | 7.0 | 6.3 | 14.8 | 15.8 | 16.9 | 18.1 | 19.3 |
| Accounts Payable, % | 26.51 | 22.24 | 16.10 | 8.55 | 7.37 | 16.15 | 16.15 | 16.15 | 16.15 | 16.15 |
| Capital Expenditure | .0 | -.2 | -1.0 | -1.8 | -1.5 | -1.0 | -1.1 | -1.2 | -1.2 | -1.3 |
| Capital Expenditure, % | -0.05 | -0.24 | -1.23 | -2.22 | -1.75 | -1.10 | -1.10 | -1.10 | -1.10 | -1.10 |
| Tax Rate, % | 0.00 | -0.39 | -1.00 | -2.21 | -31.71 | -7.06 | -7.06 | -7.06 | -7.06 | -7.06 |
| EBITAT | -18.0 | -25.8 | -40.3 | -13.9 | 5.4 | -24.7 | -26.4 | -28.3 | -30.2 | -32.3 |
| Depreciation | 8.8 | 8.6 | 12.0 | 3.3 | 2.8 | 8.8 | 9.4 | 10.1 | 10.7 | 11.5 |
| Changes in Account Receivables | -0.2 | -1.0 | -1.2 | -1.2 | -1.3 | |||||
| Changes in Inventories | -16.4 | -1.4 | -1.6 | -1.7 | -1.8 | |||||
| Changes in Accounts Payable | 8.5 | 1.0 | 1.1 | 1.2 | 1.2 | |||||
| Capital Expenditure | 0.0 | -0.2 | -1.0 | -1.8 | -1.5 | -1.0 | -1.1 | -1.2 | -1.2 | -1.3 |
| UFCF | -30.0 | -21.1 | -23.8 | -5.9 | 4.8 | -24.9 | -19.5 | -21.0 | -22.4 | -24.0 |
| WACC, % | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 |
| PV UFCF | -21.9 | -15.1 | -14.2 | -13.3 | -12.5 | |||||
| SUM PV UFCF | -77.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -24.5 | |||||||||
| Terminal Value | -205.2 | |||||||||
| Present Terminal Value | -106.9 | |||||||||
| Enterprise Value | -183.9 | |||||||||
| Net Debt | 40.0 | |||||||||
| Equity Value | -223.9 | |||||||||
| Diluted Shares Outstanding, MM | 49.0 | |||||||||
| Equity Value Per Share | -4.57 |
What You Will Get
- Real Theratechnologies Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Theratechnologies’ fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Theratechnologies Inc. (THTX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to Theratechnologies Inc. (THTX).
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Theratechnologies Inc. (THTX) projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Theratechnologies Inc. (THTX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis of Theratechnologies Inc. (THTX).
How It Works
- Download the Template: Get instant access to the Excel-based THTX DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Theratechnologies’ intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator for Theratechnologies Inc. (THTX)?
- Accuracy: Leverages real Theratechnologies financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision typically expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Theratechnologies Inc.'s (THTX) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and validate financial forecasts for THTX.
- Biotech Entrepreneurs: Understand the valuation strategies of publicly traded biotech firms like Theratechnologies Inc. (THTX).
- Consultants: Create comprehensive valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation practices relevant to the biotech industry.
What the Template Contains
- Historical Data: Includes Theratechnologies Inc.'s (THTX) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Theratechnologies Inc.'s (THTX) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Theratechnologies Inc.'s (THTX) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.